Evidence map›Paper›PMID 42052146›Full record

ReviewFrontiers in allergy2026

Asthma and corticosteroids "

Luca Borsari, Laura Carbonieri, Luca M Verdini, Valentina Ruggieri, Bianca Beghe'

Abstract readReview
In one paragraph

Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luca BorsariDepartment of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Laura CarbonieriDepartment of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Luca M VerdiniDepartment of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Valentina RuggieriDepartment of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Bianca Beghe'Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is a chronic, heterogeneous respiratory disease that affects more than 300 million individuals worldwide and is responsible for substantial morbidity, mortality and healthcare burden. Chronic airway inflammation plays a central role in symptom expression, disease progression, and response to therapy. Corticosteroids, both inhaled and systemic, are the cornerstone of asthma treatment. However, it is well known that the use and abuse of systemic corticosteroids is almost invariably associated to the development of significant acute and chronic adverse events. Epidemiological data report that despite the availability of new target therapy, e.g., biologics, in real practice systemic steroids are still overused, and in this review, we highlight strategies 1) to identify and screen patients at risk of developing corticosteroids adverse events and 2) to reduce them.

Indexed as

adverse eventsairway inflammationbiologicscorticosteroidscorticosteroid stewardshipinhaledpharmacological strategiesscreening

Identifiers

PMID42052146
PMCPMC13111361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.